Data ArticleData on synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel NURR1/NOT agonist potentially useful for the treatment of Parkinson's disease

Add time:08/20/2019    Source:sciencedirect.com

This article describes the chemical synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel Nurr1/NOT agonist. It is meant as a support to an article recently published in Bioorganic and Medicinal chemistry Letters and entitled “Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease” [1] and presenting the discovery, scope and potential of these new ligands of these nuclear receptors.

We also recommend Trading Suppliers and Manufacturers of Ethanone,2-broMo-1-iMidazo[1,2-a]pyridin-3-yl- (cas 113559-18-5). Pls Click Website Link as below: cas 113559-18-5 suppliers

Prev:Cardiovascular pharmacologyEffects of selective IKr channel blockade by E-4031 (cas 113559-13-0) on ventricular electro-mechanical relationship in the halothane-anesthetized dogs
Next:Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors)